Mustang Bio Inc. (MBIO) Financial Statements (2024 and earlier)

Company Profile

Business Address 377 PLANTATION STREET
WORCESTER, MA 01605
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments6,234,0009,562,00015,385,00058,098,00075,656,00091,364,000
Cash and cash equivalents6,234,0009,562,00015,385,00058,098,00075,656,00091,364,000
Restricted cash and investments     1,000,000 
Disposal group, including discontinued operation   4,348,000   
Other undisclosed current assets5,112,0004,026,0002,843,0003,033,0002,196,0003,083,000
Total current assets:11,346,00013,588,00022,576,00061,131,00078,852,00094,447,000
Noncurrent Assets
Operating lease, right-of-use asset1,566,0001,644,0001,721,0002,812,0002,918,0003,024,000
Property, plant and equipment3,218,0003,502,0003,786,0008,657,0009,391,00010,045,000
Restricted cash and investments750,000750,000750,000750,0001,000,0001,000,000
Other noncurrent assets833,0001,083,000253,000257,000261,000320,000
Other undisclosed noncurrent assets 29,000     
Total noncurrent assets:6,396,0006,979,0006,510,00012,476,00013,570,00014,389,000
TOTAL ASSETS:17,742,00020,567,00029,086,00073,607,00092,422,000108,836,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:14,017,00012,708,00011,684,00011,438,00013,731,00012,810,000
Accounts payable6,322,0005,498,0006,712,0006,403,0006,833,0007,005,000
Other undisclosed accounts payable and accrued liabilities7,695,0007,210,0004,972,0005,035,0006,898,0005,805,000
Due to related parties601,000766,000152,000
Other undisclosed current liabilities1,354,0001,458,0001,180,000629,000612,000595,000
Total current liabilities:15,371,00014,166,00012,864,00012,668,00015,109,00013,557,000
Noncurrent Liabilities
Long-term debt and lease obligation    27,579,00027,436,00030,684,000
Long-term debt, excluding current maturities    27,579,00027,436,00027,293,000
Liabilities, other than long-term debt2,248,0002,392,0002,509,0003,545,0003,604,000270,000
Deferred revenue270,000270,000270,000270,000270,000270,000
Operating lease, liability1,978,0002,122,0002,239,0003,275,0003,334,0003,391,000
Total noncurrent liabilities:2,248,0002,392,0002,509,00031,124,00031,040,00030,954,000
Total liabilities:17,619,00016,558,00015,373,00043,792,00046,149,00044,511,000
Equity
Equity, attributable to parent, including:123,0004,009,00013,713,00029,815,00046,273,00064,325,000
Common stock, value, subscriptions 591,0004,000  1,109,0004,000
Additional paid in capital380,502,000376,359,000376,009,000375,876,000374,522,000374,045,000
Accumulated deficit(380,971,000)(372,355,000)(362,297,000)(346,062,000)(329,369,000)(309,735,000)
Other undisclosed equity, attributable to parent1,0001,0001,0001,00011,00011,000
Total equity:123,0004,009,00013,713,00029,815,00046,273,00064,325,000
TOTAL LIABILITIES AND EQUITY:17,742,00020,567,00029,086,00073,607,00092,422,000108,836,000

Income Statement (P&L) (USD)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
Operating expenses(8,741,000)(10,307,000)(13,891,000)(16,321,000)(19,432,000)(18,848,000)
Operating loss:(8,741,000)(10,307,000)(13,891,000)(16,321,000)(19,432,000)(18,848,000)
Nonoperating income (expense)125,000249,000(2,344,000)(372,000)(202,000)(149,000)
Interest and debt expense3,000(4,000)(2,795,000)(1,176,000)(1,160,000)(1,034,000)
Loss from continuing operations:(8,613,000)(10,062,000)(19,030,000)(17,869,000)(20,794,000)(20,031,000)
Loss before gain (loss) on sale of properties:(20,031,000)
Net loss:(8,613,000)(10,062,000)(19,030,000)(17,869,000)(20,794,000)(20,031,000)
Other undisclosed net income (loss) attributable to parent(3,000)4,0002,795,0001,176,0001,160,0001,034,000
Net loss available to common stockholders, diluted:(8,616,000)(10,058,000)(16,235,000)(16,693,000)(19,634,000)(18,997,000)

Comprehensive Income (USD)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
Net loss:(8,613,000)(10,062,000)(19,030,000)(17,869,000)(20,794,000)(20,031,000)
Comprehensive loss, net of tax, attributable to parent:(8,613,000)(10,062,000)(19,030,000)(17,869,000)(20,794,000)(20,031,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: